MG
OCUL icon

Marex Group’s Ocular Therapeutix OCUL Stock Holding History

Marex Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$117K – 1095
2025
Q3 		$117K Sell
10,000
-2,358
-19% -$28.2K ﹤0.01% 769
2025
Q2 		$115K Buy
+12,358
New +$96.7K ﹤0.01% 559

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group's OCUL Position: Q4 2025 in Review

Marex Group sold out of Ocular Therapeutix (OCUL) in Q4 2025, closing a stake of 10,000 shares — an estimated $117K sold.

Marex Group first reported a position in OCUL in Q2 2025 and held it in 2 quarters. The position peaked at $117K in Q3 2025. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

  • Marex Group reported no remaining Ocular Therapeutix position as of Q4 2025 after selling out during the quarter.
  • Marex Group sold 10,000 Ocular Therapeutix shares in Q4 2025, an estimated $117K.
  • Marex Group first reported a position in Ocular Therapeutix in Q2 2025 and held it in 2 quarters.
  • Marex Group's Ocular Therapeutix position peaked at $117K in Q3 2025.
  • 249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Marex Group's 13F filing for Q4 2025, filed 12 Feb 2026.